Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials.

Franquesa, Marcella; Hoogduijn, Martin J.; Reinders, Marlies E.; Eggenhofer, Elke; Engela, Anja U.; Mensah, Fane K.; Torras, Joan; Pileggi, Antonello; van Kooten, Cees; Mahon, Bernard; DETRY, Olivier; Popp, Felix C.; Benseler, Volker; Casiraghi, Federica; Johnson, Christian; Ancans, Janis; Fillenberg, Barbara; Delarosa, Olga; Aran, Josep M.; Roemeling-Vanrhijn, Marieke; Pinxteren, Jef; Perico, Norberto; Gotti, Eliana; Christ, Bruno; Reading, James; Introna, Martino; Deans, Robert; Shagidulin, Murat; Farre, Ramon; Rambaldi, Alessandro; Sanchez-Fueyo, Albert; Obermajer, Natasha; Pulin, Andrey; Dor, Frank J. M. F.; Portero-Sanchez, Isabel; Baan, Carla C.; Rabelink, Ton J.; Remuzzi, Giuseppe; Betjes, Michiel G. H.; Dahlke, Marc H.; Grinyo, Josep M.

doi:10.1097/TP.0b013e318298f9fa

Article (Scientific journals)

Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials.

Franquesa, Marcella; Hoogduijn, Martin J.; Reinders, Marlies E. et al.

2013 • In Transplantation, 96 (3), p. 234-238

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/150750

DOI
10.1097/TP.0b013e318298f9fa

PubMed
23759879

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

MISOT2012.pdf

Publisher postprint (167.53 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] The Fourth Expert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took place in Barcelona on October 19 and 20, 2012. This meeting focused on the translation of preclinical data into early clinical settings. This position paper highlights the main topics explored on the safety and efficacy of mesenchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (proper timing, concomitant immunossupression, source and immunogenicity of mesenchymal stem cells, and oncogenicity) that have been addressed and will be followed up by the MiSOT Consortium in future studies.

Disciplines :

Surgery

Author, co-author :

Franquesa, Marcella

Hoogduijn, Martin J.

Reinders, Marlies E.

Eggenhofer, Elke

Engela, Anja U.

Mensah, Fane K.

Torras, Joan

Pileggi, Antonello

van Kooten, Cees

Mahon, Bernard

More authors (31 more)

Language :

English

Title :

Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials.

Publication date :

August 2013

Journal title :

Transplantation

ISSN :

0041-1337

eISSN :

1534-6080

Publisher :

Lippincott Williams & Wilkins, Hagerstown, United States - Maryland

Volume :

Issue :

Pages :

234-238

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 June 2013

Statistics

Number of views

76 (5 by ULiège)

Number of downloads

6 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Dahlke MH, Hoogduijn M, Eggenhofer E, et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009; 88: 614.
Hoogduijn MJ, Popp FC, Grohnert A, et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010; 90: 124.
Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412.
Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307: 1169.
Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrowderived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2: 107.
Detry O. Mesenchymal stem cells after renal or liver transplantation. ClinicalTrials.gov Identifier: NCT01429038, September 1, 2011.
Remuzzi G. Mesenchymal stem cells under basiliximab/low dose RATG to induce renal transplant tolerance. ClinicalTrials.gov Identifier: NCT00752479, July 23, 2008.
Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of thirdparty multipotent adult progenitor cells for immunomodulation therapy after liver transplantationVa phase I study (MISOT-I). J TranslMed 2011; 9: 124.
Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of human mesenchymal stem cells to tacrolimus,mycophenolic acid, and rapamycin. Transplantation 2008; 86: 1283.
Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011; 25: 141.
Roemeling-van Rhijn M, Reinders ME, de Klein A, et al.Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 2012; 82: 748.
Reinders ME, Roemeling-van Rhijn M, Khairoun M, et al. Bone marrow-derived mesenchymal stromal cells from patients with endstage renal disease are suitable for autologous therapy. Cytotherapy 2013; 15: 663.
Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013; 95: 161.
Casiraghi F, Remuzzi G, Abbate M, et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2012; 9: 65.
Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects crosscontamination: putting the research field on track [letter]. Cancer Res 2010; 70: 6393.
Vogel G. Cell biology. To scientists' dismay, mixed-up cell lines strike again. Science 2010; 329: 1004.
Ancans J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front Immunol 2012; 3: 253.
Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297.
Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance' Immunology 2012; 137: 206.